IDP-NS16
General Information
DRACP ID DRACP01777
Peptide Name IDP-NS16
Sequence RQRRNDLXSSFLTLXDH
Sequence Length 17
UniProt ID Not available
PubChem CID Not available
Origin Synthetics
Type Synthetic peptide
Classification
Active ACP
Activity Information
Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
---|---|---|---|---|---|---|
RG1, epithelial (glioblastoma, GMB), from surgical specimens from patients | Glioblastoma | Blastoma | EC50≈15 μM | CYTELL assay | 72-96 h | Patent |
12O53, epithelial (glioblastoma, GMB), from surgical specimens from patients | Glioblastoma | Blastoma | EC50≈10 μM | CYTELL assay | 72-96 h | Patent |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer; Antitumor
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Free
Other Modification X=—(CH2)6—CH═CH—(CH2)3— (for the cases NS10, NS16 and Na05) links both Xs radicals in each sequence
Chiral L
Physicochemical Information
Formula C78H124N28O23
Absent amino acids ACEGIKMPVWY
Common amino acids LR
Mass 232758
Pl 10.31
Basic residues 4
Acidic residues 2
Hydrophobic residues 4
Net charge 2
Boman Index -7067
Hydrophobicity -110.59
Aliphatic Index 68.82
Half Life
/
Extinction Coefficient cystines 0
Absorbance 280nm 0
Polar residues 4
Amino acid distribution
Literature Information
Literature 1
Pubmed ID Not available
Title Not available
Doi Not available
Year Not available
Patent
Patent ID US2020/0157150A1
Patent Title Anticancer Peptides
Other Iinformation Patent Application; Family: 8s / 8ex; Family Jurisdictions: CA, CN, US, AU, JP, EP, WO, KR; Legal Status: Pending; Application No: 201816635902; Filed: Jul 31, 2018; Published: May 21, 2020; Earliest Priority: Aug 1, 2017
Other Published ID AU2018311129A1 CA3071601A1 CN111436200A EP3661947A1 JP2020529429A KR20200032730A WO2019025432A1